NAP1L1 is a key regulator of embryonic neurogenesis but its role in lung cancer remains unexplored. In this study, we investigated the relationship between NAP1L1 expression and the clinicopathological parameters and prognosis of non-small cell lung cancer patients. To this end, the expression of NAP1L1 in tumor samples was evaluated by immunohistochemistry. NAP1L1 expression was significantly associated with reduced differentiation (P = 0.00014), higher pathological TNM stages (P < 0.00001), lymph node metastasis (P < 0.00001), intrapulmonary metastasis (P = 0.02955), lymphatic invasion (P = 0.00019), vascular invasion (P = 0.00008) and poorer prognosis (P = 0.0008) of patients with adenocarcinoma. Moreover, multivariate analyses using the Cox-proportional hazards model confirmed that NAP1L1 expression increased the risk of death after adjusting for other clinicopathological factors (HR = 2.46, 95% CI, 1.22-4.96). Furthermore, NAP1L1 expression was identified as an independent poor prognostic factor in patients with resectable stage I lung adenocarcinoma. NAP1L1-siRNA-treated lung adenocarcinoma-derived A549 cells showed significant suppression of proliferation, migration, and invasion abilities. These findings suggest that NAP1L1 may be a novel predictive and prognostic marker in lung adenocarcinoma, particularly in those with stage I of the disease.

中文翻译：

---

NAP1L1表达在早期肺腺癌患者中的预后意义。

NAP1L1是胚胎神经发生的关键调节剂，但其在肺癌中的作用尚待探索。在这项研究中，我们调查了NAP1L1表达与非小细胞肺癌患者临床病理参数和预后之间的关系。为此，通过免疫组织化学评估了NAP1L1在肿瘤样品中的表达。NAP1L1表达与分化程度降低（P = 0.00014），较高的病理TNM分期（P <0.00001），淋巴结转移（P <0.00001），肺内转移（P = 0.02955），淋巴管浸润（P = 0.00019），血管显着相关侵袭性（P = 0.00008）和预后较差（P = 0.0008）的腺癌患者。此外，使用Cox比例风险模型进行的多变量分析证实，调整了其他临床病理因素后，NAP1L1表达增加了死亡风险（HR = 2.46，95％CI，1.22-4.96）。此外，NAP1L1表达被确定为可切除的I期肺腺癌患者的独立不良预后因素。NAP1L1-siRNA处理的肺腺癌衍生的A549细胞显示出明显的增殖，迁移和侵袭能力抑制。这些发现表明，NAP1L1可能是肺腺癌（尤其是患有该病I期的那些）中的新型预测和预后标志物。NAP1L1表达被确定为可切除的I期肺腺癌患者的独立不良预后因素。NAP1L1-siRNA处理的肺腺癌衍生的A549细胞显示出明显的增殖，迁移和侵袭能力抑制。这些发现表明，NAP1L1可能是肺腺癌（尤其是患有该病I期的那些）中的新型预测和预后标志物。NAP1L1表达被确定为可切除的I期肺腺癌患者的独立不良预后因素。NAP1L1-siRNA处理的肺腺癌衍生的A549细胞显示出明显的增殖，迁移和侵袭能力抑制。这些发现表明，NAP1L1可能是肺腺癌（尤其是患有该病I期的那些）中的新型预测和预后标志物。